Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors. Consistent with this, we describe here objective responses in two patients (at 300 mg daily) with advanced KRASG12X lung and pancreatic adenocarcinoma, respectively, demonstrating the initial activity of RMC-6236 in an ongoing phase I/Ib clinical trial (NCT05379985). Significance: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition is tolerable at exposures that induce profound tumor regressions in preclinical models of, and in patients with, such tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. RMC-6236 is a potent noncovalent inhibitor of the GTP-bound state of multiple RAS variants in vitro. A, Chemical structure of RMC-6236. B, Biochemical potency of RMC-6236 for wild-type KRAS, NRAS, HRAS, and several oncogenic RAS variants. EC50 values shown for inhibition of RAS-RAF binding using recombinant proteins in vitro. Error bars indicate ± 95% CI. C, Immunoblot protein Western analyses of KRAS pathway targets in HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) cancer cells treated with RMC-6236 at the indicated concentrations and time points. D, RMC-6236 potency measured in the PRISM panel of cancer cell lines. Left, AUC difference between cell lines with and without a given gene mutation (x-axis) and the significance of the difference (y-axis). Points represent mutated genes. A negative AUC indicates increased sensitivity to RMC-6236 and positive AUC indicates resistance. Horizontal dashed line represents the P-value cutoff of 5 × 10−8. Vertical lines represent the absolute effect cutoff of 0.1. Right: AUC for KRAS mutant [glycine 12 depicted as KRASG12X (115 lines); all other KRAS mutations labeled KRASOther (42 lines)], NRAS mutant [glutamine 61 depicted as NRASQ61X (34 lines); all other NRAS mutations labeled as NRASOther (20 lines)], HRAS mutant, NF1 mutant, EGFR mutant, PTPN11 mutant, and BRAFV600E mutant cell lines are shown. Comparison of indicated groups was done by the Wilcoxon rank-sum test with continuity correction. (**, P < 0.01; ***, P < 0.001).](https://figures.cochat.ai/paper-figures/a34ae485387a4becada99a3f23c46e13/translational-and-therapeutic-evaluation-of-ras-gtp-inhibition-by-rmc-6236-in-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent preclinical study on pan-RAS inhibitor RMC-6236 identified an association between CDKN2A loss and reduced response in KRAS G12-mutant NSCLC [44].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · cited 2×
“F), wherein tumor progression was defined as individual tumor volume doubling from baseline (29), showed that RMC-6236 treatment resulted in significantly improved progression-free survival (PFS) as compared with vehicle controls in all KRAS G12X tumor-bearing animals.”
Self-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 2×
“Until the recent development of direct inhibitors of KRAS G12C , RAS was largely considered undruggable (4).”
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061 · cited 2×
“The advent of inactive-state KRAS G12C inhibitors has provided an elegant clinical proof of concept for the benefits of targeting mutant KRAS, resulting in a surfeit of covalent KRAS G12C inhibitors entering clinical evaluation (9, 10, 37).”
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · cited 2×
“…that of the prevalent genomic aberrations re-ported to modify responses to targeted RAS pathway inhibition with approved KRAS G12C inhibitors (32, 33), mutations in SMARCA4 were not associated with impaired RMC-6236 effects on durability of response in KRAS G12X NSCLC xenograft models, while…”
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875 · cited 1×
“Direct pharmacologic targeting of canonical RAS proteins has been an aspirational goal since the discovery of the RAS oncogenes over 40 years ago (47, 48).”
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 1×
“…to be particularly addicted to oncogenic RAS signaling, exemplified by Kras G12D inactivation studies in genetically engineered mouse models (6), pharmacologic inhibition of KRAS G12D in preclinical models (7, 8), and most recently illustrated by the clinical activity of KRAS G12C…”
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769 · cited 16×
“S2B) and KP-4 ( KRAS G12D/WT , PDAC; Supplementary Fig.”
InfluentialHaigis, K. M., Kendall, K. R., Wang, Y., Cheung, A., Haigis, M. C., Glickman, J. N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold, J., Shannon, K. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.115 · Cited by 610
Self-citationCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592 · cited 7×
“In each of these cases, preexisting and acquired KRAS codon 12, 13, and 61 mutations, and second-site alterations in cis within the KRAS G12C allele itself, have been commonly observed.”
InfluentialAnti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · cited 2×
“…oncogenic KRAS point mutations (capable of driving tumorigenesis) is often exploited to reactivate RAS signaling and drive resistance following treatment with KRAS mutant-selective therapies, e.g., in patients with KRAS G12C NSCLC tumors treated with sotorasib, adagrasib, or divarasib (22, 23, 37).”
Simeoni, M., Magni, P., Cammia, C., De Nicolao, G., Croci, V., Pesenti, E., Germani, M., Poggesi, I., & Rocchetti, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2524 · Cited by 506
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · cited 2×
“…models; this may reflect the presence of multiple oncogenic drivers and/or EGFR-mediated adaptive feedback to RAS/MAPK pathway signaling inhibition that is particularly resilient in colorectal cancer, as has been observed following BRAF and/or inactive-state selective KRAS G12C inhibition (13, 14).”
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479 · cited 1×
“…oncogenic KRAS point mutations (capable of driving tumorigenesis) is often exploited to reactivate RAS signaling and drive resistance following treatment with KRAS mutant-selective therapies, e.g., in patients with KRAS G12C NSCLC tumors treated with sotorasib, adagrasib, or divarasib (22, 23, 37).”
Self-citationImmune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370
Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.037 · Cited by 348
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303810 · Cited by 328 · cited 2×
“…oncogenic KRAS point mutations (capable of driving tumorigenesis) is often exploited to reactivate RAS signaling and drive resistance following treatment with KRAS mutant-selective therapies, e.g., in patients with KRAS G12C NSCLC tumors treated with sotorasib, adagrasib, or divarasib (22, 23, 37).”
Self-citationFakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320 · cited 1×
“…the reduced and more heterogeneous response to inactive-state selective KRAS G12C inhibitors that has been observed thus far in colorectal cancer as compared with that in NSCLC, and the significant combination benefit that has been observed for these inhibitors with anti-EGFR antibodies (15, 16).”
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Soucek, L., Whitfield, J. R., Sodir, N. M., Massó-Vallés, D., Serrano, E., Karnezis, A. N., Swigart, L. B., & Evan, G. I. (2013) · Genes & Development · doi:10.1101/gad.205542.112 · Cited by 301
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Self-citationRAS pathways to cell cycle control and cell transformation
Pellicer, A. (1998) · Frontiers in Bioscience · doi:10.2741/a331 · Cited by 248
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208 · cited 2×
“The relative representation of oncogenic RAS variants is highly variable across cancer types, likely due to an interplay between allele-specific biochemical, structural, and signaling distinctions and tissue (indication)-specific properties (3, 5).”
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203 · cited 3×
“Using whole-transcriptome and whole-exome sequencing, we also examined alterations in key genes implicated in NSCLC, PDAC, and colorectal cancer disease etiology (30–32).”
Sansom, O. J., Meniel, V., Wilkins, J. A., Cole, A. M., Oien, K. A., Marsh, V., Jamieson, T. J., Guerra, C., Ashton, G. H., Barbacid, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604130103 · Cited by 187
Mechanisms of Resistance to KRASG12C-Targeted Therapy
Akhave, N. S., Biter, A. B., & Hong, D. S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1616 · Cited by 156
Rogers, Z. N., McFarland, C. D., Winters, I. P., Naranjo, S., Chuang, C.-H., Petrov, D., & Winslow, M. M. (2017) · Nature Methods · doi:10.1038/nmeth.4297 · Cited by 147
Self-citationRas/Erk MAPK Signaling in Epidermal Homeostasis and Neoplasia
Khavari, T. A., & Rinn, J. L. (2007) · Cell Cycle · doi:10.4161/cc.6.23.4998 · Cited by 142
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0383 · Cited by 135
Self-citationArbour, K. C., Punekar, S. R., Garrido‐Laguna, I., Hong, D. S., Wolpin, B. M., Pelster, M. S., Barve, M., Starodub, A., Sommerhalder, D., Chang, S. S., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.1838 · Cited by 130
Self-citationRapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120 · cited 1×
“These compounds are derived from sanglifehrin A, which binds the abundant immunophilin cyclophilin A (CypA, HUGO symbol PPIA) with high affinity (24) and is a member of a class of natural products that inspired a paradigm for inhibiting undruggable targets (25, 26).”
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
Fernandes Neto, J. M., Nadal, E., Bosdriesz, E., Ooft, S. N., Farre, L., McLean, C., Klarenbeek, S., Jurgens, A., Hagen, H., Wang, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16952-9 · Cited by 92
Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D
Zheng, Q., Zhang, Z., Guiley, K. Z., & Shokat, K. M. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01565-w · Cited by 88
Shigdel, U. K., Lee, S.-J., Sowa, M. E., Bowman, B. R., Robison, K., Zhou, M., Pua, K. H., Stiles, D. T., Blodgett, J. A. V., Udwary, D. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006560117 · Cited by 80
Wong, H., Vernillet, L., Peterson, A., Ware, J. A., Lee, L., Martini, J.-F., Yu, P., Li, C., Rosario, G. D., Choo, E. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0445 · Cited by 79
Enhancing the landscape of colorectal cancer using targeted deep sequencing
Lee, C. S., Song, I. H., Lee, A., Kang, J., Lee, Y. S., Lee, I. K., Song, Y. S., & Lee, S. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-87486-3 · Cited by 64
Vassella, E., Kashani, E., Zens, P., Kündig, A., Fung, C., Scherz, A., Herrmann, E., Ermis, E., Schmid, R. A., & Berezowska, S. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.006 · Cited by 49
Targeting KRAS mutant lung cancer: light at the end of the tunnel
Drosten, M., & Barbacid, M. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 47
Kras is Required for Adult Hematopoiesis
Damnernsawad, A., Kong, G., Wen, Z. H., Liu, Y., Rajagopalan, A., You, X., Wang, J., Zhou, Y., Ranheim, E. A., Luo, H. R., et al. (2016) · Stem Cells · doi:10.1002/stem.2355 · Cited by 44
More to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44 · cited 2×
“We hypothesized that, in contrast to mutant RAS-addicted tumor cells, normal cells have reduced levels and/or dependence on RAS-GTP and use homeostatic mechanisms to restore equilibrium following perturbation of RAS signaling (43, 44).”
Injury prevents Ras mutant cell expansion in mosaic skin
Gallini, S., Annusver, K., Rahman, N.-T., Gonzalez, D. G., Yun, S., Matte-Martone, C. C., Xin, T., Lathrop, E., Suozzi, K. C., Kasper, M., et al. (2023) · Nature · doi:10.1038/s41586-023-06198-y · Cited by 43
Oncogenic context shapes the fitness landscape of tumor suppression
Blair, L. M., Juan, J. M., Sebastian, L., Tran, V. B., Nie, W., Wall, G. D., Gerceker, M., Lai, I. K., Apilado, E. A., Grenot, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42156-y · Cited by 42
Self-citationXiong, W., Friese‐Hamim, M., Johne, A., Stroh, C., Klevesath, M., Falchook, G. S., Hong, D. S., Girard, P., & Bawab, S. E. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12602 · Cited by 33
Role of Ras in regulation of intestinal epithelial cell homeostasis and crosstalk with Wnt signaling
Kotani, T., Ihara, N., Okamoto, S., Setiawan, J., Konno, T., Saito, Y., Murata, Y., & Matozaki, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256774 · Cited by 8
Research works printed but not linked: 1
- Lietman, 2022, More to the RAS Story: KRASG12C inhibition, resistance mechanisms, and moving beyond KRASG12C, Am Soc Clin Oncol Educ Book, 42, 1
Cited by
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
Self-citationKRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Cregg, J., Edwards, A. V., Chang, S., Lee, B. J., Knox, J. E., Tomlinson, A. C. A., Marquez, A., Liu, Y., Freilich, R., Aay, N., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02314 · Cited by 151
Self-citationDaraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2605555 · Cited by 147
Self-citationRAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Metadata
- Authors
- Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., Brodbeck, J., Chen, Z., Wei, X., Rosen, M. J., Gindin, Y., Lee, B. J., Evans, J. W., Chang, S., Wang, Z., Seamon, K. J., Parsons, D., Cregg, J., Marquez, A., Tomlinson, A. C. A., Yano, J. K., Knox, J. E., Quintana, E., Aguirre, A. J., Arbour, K. C., Reed, A., Gustafson, W. C., Gill, A. L., Koltun, E. S., Wildes, D., Smith, J. A. M., Wang, Z., & Singh, M.
- Affiliations
- Revolution Medicines (United States) (US)
- NortonLifeLock (United States) (US)
- Broad Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Christ Hospital (US)
- Corresponding author
- Wang, Zhengping
- Singh, Mallika
- ORCID
- Jiang, Jingjing
- Jiang, Lingyan
- Maldonato, Benjamin J.
- Wang, Yingyun
- Holderfield, Matthew
- Aronchik, Ida
- Winters, Ian P.
- Salman, Zeena
- Blaj, Cristina
- Menard, Marie
- Brodbeck, Jens
- Chen, Zhe
- Wei, Xing
- Rosen, Michael J.
- Gindin, Yevgeniy
- Lee, Bianca J.
- Evans, James W.
- Chang, Stephanie
- Wang, Zhican
- Seamon, Kyle J.
- Parsons, Dylan
- Cregg, James
- Marquez, Abby
- Tomlinson, Aidan C.A.
- Yano, Jason K.
- Knox, John E.
- Quintana, Elsa
- Aguirre, Andrew J.
- Arbour, Kathryn C.
- Reed, Abby
- Gustafson, W. Clay
- Gill, Adrian L.
- Koltun, Elena S.
- Wildes, David
- Smith, Jacqueline A.M.
- Wang, Zhengping
- Singh, Mallika
- Venue
- Cancer Discovery
- Published
- 2024-04-09
- Volume
- 14
- Issue
- 6
- Pages
- 994-1017
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11149917
- OpenAlex
- W4394595642
- Cited by
- 343
- References
- 51
- Citations by year
- 2026: 149 · 2025: 150 · 2024: 44
- FWCI
- 46.56
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-10-06)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- RMC-6236, RAS-driven cancers, RAS wild-type, lung adenocarcinoma, pancreatic ductal adenocarcinoma, pharmacokinetic-pharmacodynamic modeling, tumor regression
- MeSH terms
- Animals, Antineoplastic Agents, Female, Guanosine Triphosphate, Humans, Lung Neoplasms, Male, Mutation, Neoplasms, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.